R&D News | pharmaphorum

News

BMS gets new OK for Opdivo/Yervoy in kidney cancer

Bristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green light from the European Medicines Agency (EMA) for its use in renal

News

Pfizer set for July FDA verdict on rare heart disease drug

Pfizer is finally closing on approval of its rare disease therapy tafamidis in the US, several years after it first reached the market in Europe.

News

IFPMA’s new code bans all gifts – no exceptions!

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has published its new code of practice, introducing a total ban on gifts and promotional items for pres

News

Daiichi Sankyo takes option on diabetes stem cell start-up

Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells.

News

Close up view of young woman holding ginseng vitamins and minerals pills in hand with capsule bottle on table. High angle view

HRT tablets linked to higher blood clot risk: study

Certain types of hormone replacement therapy (HRT) could lead to increased risk of venous thromboembolism (VTE), a new study has suggested.

News

Sage soars on postpartum depression data

Sage Therapeutics has scored a big win with postpartum depression (PPD) drug SAGE-217, after rolling the dice on an upgraded clinical trial last summer.

BMS gets new OK for Opdivo/Yervoy in kidney cancer

Pfizer set for July FDA verdict on rare heart disease drug

IFPMA’s new code bans all gifts – no exceptions!

Daiichi Sankyo takes option on diabetes stem cell start-up

HRT tablets linked to higher blood clot risk: study

Sage soars on postpartum depression data

Electra sets terms for IPO, hoping to raise up to $347m

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks